Atossa Therapeutics Archives - PHStocks

Tuesday, May 20, 2025

Latest:

Euro Manganese Announces Results of Annual General and Special Meeting
Staying Ahead in the Digital Era as AI Takes Full Center Stage at InfoComm Asia 2025 — Visitor Registration Opens
Southeast Asian stem cell leader Medeze launches voluntary conditional cash partial offer for 10% stake in SGX-listed Cordlife Group Limited
Widespread Use Of Illicit Streaming Devices In Taiwan Poses Potential National Cybersecurity Threat, New Research FindsWidespread Use Of Illicit Streaming Devices In Taiwan Poses Potential National Cybersecurity Threat, New Research Finds
EdgePoint completes 12 projects under its Connectivity for Communities Program, impacting more than 6,500 students across Malaysia, Indonesia and the Philippines

Asia Corporate News

PHStocks 12/03/202114/03/2021 0 Comments Atossa Therapeutics, Avance Clinical

Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa